Presentation TCT 2017 Is Functional Capacity a Suitable Endpoint for Heart Failure Drug and Device Trials? Presenter: Angeles Alonso Garcia November 01, 2017 REGISTER for free or LOG IN to view this content Heart Failure Presentation TCT 2017 Heart Failure Pharma Up Next Presentation TCT 2017 Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials? Presenter: James E. Udelson November 01, 2017 More slides + Presentation TCT 2017 Devices for Cardio-Renal Failure: The Future of Heart Failure and Shock Therapies? Presenter: Navin K. Kapur November 01, 2017 Presentation TCT 2017 The Potential for Neuromodulation in Heart Failure Presenter: Felix Mahfoud November 01, 2017 We Recommend
Presentation TCT 2017 Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials? Presenter: James E. Udelson November 01, 2017
Presentation TCT 2017 Devices for Cardio-Renal Failure: The Future of Heart Failure and Shock Therapies? Presenter: Navin K. Kapur November 01, 2017
Presentation TCT 2017 The Potential for Neuromodulation in Heart Failure Presenter: Felix Mahfoud November 01, 2017